A DC vaccine generated by exposure to tumor lysate also gave clinical benefit (improved survival) and increased tumor infiltration of CD8+ T cells in patients with glioma, a poorly immunogenic tumor type [122]. This evidence concerns the gene CD8A and central nervous system cancer.